Navigation Links
DURECT to Present at the Cowen and Company Healthcare Conference
Date:3/1/2010

rugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR™, and ELADUR™ are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation

Back to top

RELATED LINKS
http://www.durect.com

'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
2. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
3. DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference Call
4. DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
5. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
6. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
7. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
8. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
9. Stryker to Present at Investor Conference
10. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
11. Hill-Rom to Present at the Canaccord Adams Musculoskeletal Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... N.Y. , Jan. 15, 2014 Sono-Tek Corporation (OTC ... months ended November 30, 2013, compared to sales of $2,202,000 ... 20%. Once again, this quarter has also shown growth over ... the first quarter of this fiscal year. Markets that experienced ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
Breaking Medicine Technology:Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3
... 20 Radius Health ("Radius") announced today that it ... institutional financing round, increasing total Series C investment to ... company,s inception to $106.5 million. All existing institutional investors ... NVS Strategic Fund and including MPM Capital, The Wellcome ...
... Amgen,(Nasdaq: AMGN ) and Millennium: ... Company Limited (TSE: 4052), today announced that,enrollment in ... 706) in,combination with paclitaxel and carboplatin for the ... has been temporarily suspended,following a planned safety data ...
Cached Medicine Technology:Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7
(Date:7/11/2014)... 2014 The report, “Specialty Synthetic ... & Geography - 2018,” defines and segments the ... an analysis and forecast of the volumes and ... (Para aramids, meta aramids, UHMW Polyethylene, carbon fiber, ... fiber, PBI fiber, PBO fiber, and liquid crystal ...
(Date:7/11/2014)... July 11, 2014 Utilizing the Keller ... Dr. William Koenig, has topped a record number of ... has performed over 400 successful procedures without the occurrence ... is well known across the country for his expertise ... record has long been the foundation for numerous studies ...
(Date:7/11/2014)... 2014 (HealthDay News) -- Children who have emergency ... complications and potentially even death than those who ... However, the Johns Hopkins researchers noted that ... researchers analyzed data on nearly 440,000 simple emergency ... over a 22-year period. The surgeries are ...
(Date:7/11/2014)... 11, 2014 The report “Probiotics ... Nutrients, Animal Feed), Applications (Regular, Therapeutic, Preventive Health ... Trends & Forecasts to 2019 ” defines and ... and forecasting of the market value of probiotic ... driving and restraining factors for the global market ...
(Date:7/11/2014)... Global enterprises today are shifting towards the ... activities. Managed services offer these global enterprises a strategic ... resulted into rising operational costs to companies. The aim ... be the global market driver for expanding the managed ... services market is estimated to grow from $142.75 billion ...
Breaking Medicine News(10 mins):Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4
... June 5 The combination of two different chemotherapies ... cancers is not effective against advanced melanoma, according to ... 46th annual meeting of the American Society of Clinical ... we learn something important about the treatment of melanoma," ...
... ... that a less-invasive technique called sentinel node resection is just as safe ... the underarm area, according to a new study being presented today at ... National Surgical Adjuvant Breast and Bowel Project (NSABP) and Allegheny General Hospital ...
... chemotherapy, new drug prolonged lives of some with advanced ... report they prolonged survival for some patients with advanced ... is currently only about six months. , One ... tumors in the majority of lung cancer patients with ...
... drugs approved for treatment of drug-resistant chronic myeloid leukemia ... therapy than the existing front-line medication, according to two ... of Medicine . Separate international phase III ... treatment between the standard-of-care drug imatinib, also known as ...
... CHICAGO - Dasatanib, a medication currently approved as treatment ... quicker, better responses as a first therapy than the ... of Texas MD Anderson Cancer Center. The findings ... American Society of Clinical Oncology today, and published in ...
... early because of supplement,s poor performance , SATURDAY, June ... selenium doesn,t reduce the likelihood of lung cancer recurrence, ... D. Karp, a professor in the department of thoracic/head ... M.D. Anderson Cancer Center, is scheduled to present the ...
Cached Medicine News:Health News:Combination treatment regimen not effective against advanced melanoma 2Health News:Less-invasive Lymph Node Resection Following Breast Cancer Surgery Confirmed as Standard of Care in Eight-year Study Led by AGH Doctors 2Health News:Researchers Report Treatment Headway Against Lung Cancer 2Health News:Researchers Report Treatment Headway Against Lung Cancer 3Health News:Second-line CML drugs evoke faster, better front-line remissions 2Health News:Second-line CML drugs evoke faster, better front-line remissions 3Health News:Second-line CML drug evokes faster response, fewer side effects, pivotal study finds 2Health News:Don't Count on Selenium to Prevent Lung Cancer Recurrence 2
... Screen Tests are available in 14 configurations ... Designed using Microgenics Antibody Technology, the SureStep ... of care immunoassay targeted to detect MDMA ... and MDEA but no cross-reactivity to any ...
AccuSign DOA Series tests include tests for Amphetamines, Barbituates, Benzodiazepines, Cocaine, Methadone, Methamphetamines, Nicotine (Cotinine), Opiates, Phencyclidine, THC, Tricyclic Antidepressan...
... The SureStep™ Drug Screen Tests are ... assay for MDMA (Ecstasy). Designed using Microgenics ... is the only point of care immunoassay ... affinity for both MDA and MDEA but ...
... Drug Screen Tests are available in 14 ... (Ecstasy). Designed using Microgenics Antibody Technology, the ... point of care immunoassay targeted to detect ... MDA and MDEA but no cross-reactivity to ...
Medicine Products: